hs-20117
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jul 20, 2023 (NCT05940116)
Timeline
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06963502 | Phase 1 | May 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06621563 | Phase 1 | Dec 1, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06417008 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2024 | Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., Tianjin Medical University |
| NCT05940116 | Phase 1 | Jul 20, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Tianjin Medical University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 4 | 4 | 2 | 2023 |
| Tianjin Medical University | Academic/Hospital | 2 | 0 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1